News

The associate professor of clinical neurology spoke about the need to understand modifiable social and cultural factors that could impact disease severity and progression.

The clinical director of the Anti-NMDA Receptor Encephalitis Foundation spoke about the insidiousness of AD and the need for diagnosis earlier in disease progression.

The announcement was discouraging to many, as only 2 agents for ALS have been granted FDA approval in as many decades.

The UC Health professor of neurology argued that with the current view on Parkinson disease, the field is missing the mark for disease-modifying interventions.

The chief medical officer and chief operating officer of Brainstorm Cell Therapeutics spoke about a host of topics related to the treatment of amyotrophic lateral sclerosis.

More than two-thirds of patients treated with intravenous infusions of the CGRP inhibitor eptinezumab had an average 50% reduction in migraines.

Study findings revealed statistically significant results at week 4 for the 100-U dose compared to placebo. The 75-U dose, while effective, did not achieve statistical significance.

The data from the phase III EXPAND study indicated to the researchers that this risk reduction obtained with siponimod was substantially isolated from MS relapse.

Chronic traumatic encephalopathy is a neurodegenerative disease that is believed to be a consequence of exposure to repetitive head impacts, including concussions and subconcussive injuries.

When and why were the Beers criteria set in place? Learn more in this quiz.

Newly approved medications for various types of pain, generalized myasthenia gravis, and Parkinson disease will be fodder for discussion at AAN 2018. Here’s a brief overview of the therapies the FDA has approved within the past 6 months.

The calcitonin gene-related peptide inhibitor lowered monthly migraine days by ≥50% in 30.3% of patients compared to 13.7% on placebo.

A photographic memory with low resolution images.

Here: the most notable changes in the new AAN guideline on mild cognitive impairment.

The program seeks to optimize small-molecule compounds to decrease the production of mHtt through PTC’s splicing platform.

This is a unique opportunity for talented early career psychiatrists and neurologists to gain experience in scholarly activities and research.

Using the NCT-504 compound to inhibit cell-signaling activity in PIP4Kγ resulted in an increase in autophagy in connective tissue cells from patients with HD.

Vagus nerve stimulation in conjunction with conventional rehabilitation services more than doubled lasting recovery in forelimb supination and simple motor tasks following a stroke.

What's the link between restrictive anorexia, anorexia nervosa, and binge eating disorder and ASD? This study sheds some light.

Alterations in the gut microbiome may trigger autoimmunity against the CNS, and contribute to the development of neuropsychiatric disorders. How? A recent review offers insights.

The treatment is the first patient-infused subcutaneous formulation of immunoglobulin to gain approval for CIDP.

Epilepsy appears to be the main reason for an increased risk of serious traffic accidents among patients with the disease -not anti-epileptic drugs.

Exposure to monesin has been shown to combat stress by oxidants and free radicals via the protein kinase R-like endoplasmic reticulum kinase/activating transcription factor 4 pathway.

This study points to nitrated nucleosomes as a promising biomarker for distinguishing neuropsychiatric events due to systemic lupus erythematosus from those secondary to other disorders.

The FDA has accepted an application for solriamfetol as a treatment for excessive sleepiness associated with narcolepsy or obstructive sleep apnea, with a PDUFA action date set for December 20, 2018.

Children exposed to antiretrovirals (ARVs) may have worse neurodevelopmental outcomes than children never exposed to ARVs according to a systematic review and meta-analysis.

Which brain regions are potential deep brain stimulation targets for neurological disorders with memory impairment? Take the quiz and learn more.

The goal for the companies is to reach greater levels of anti-tau antibodies in a single treatment that what current weekly or bi-weekly infusions can achieve.